Spotlight On... U.K.'s Oxford BioMedica gets MHRA nod for new manufacturing facility; Lonza adds mammalian biopharma capacity in U.K.; India's Marksman Pharma plant runs afoul of U.K. regulators; and more...

Oxford BioMedica says the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has given approval to its new biomanufacturing facility in Yarnton, Oxford, to manufacture bulk drug material for Investigational Medicinal Products. The company said with the new facility in operation it will have double the capacity. Oxford BioMedica also expects a capacity expansion at its other site in Oxford to be complete in the first half of this year. Release

> Swiss CDMO Lonza is adding two 1000-L single-use bioreactors at its site in Slough, U.K., to expand mammalian biopharma production. Report

> India's Marksman Pharma says U.K. regulators have found issues with its plant in Gao after an inspection in November. Report

> Zoetis ($ZTS) has struck another deal to trim its manufacturing network with a deal to sell its 55% share of a manufacturing site in Hsinchu, Taiwan, and the products it manufacturers to Yung Shin Pharmaceutical Industrial for $13 million. Filing

Suggested Articles

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back. 

The lawmakers question Kodak's fitness for such a major pharma manufacturing deal, as well as suspicious stock transactions by company leadership.

AZ's China COVID-19 vaccine deal comes after supply agreements with the U.S., the U.K., EU and Brazil, as well as licensing pacts in India and Japan.